Medico-Economic Evaluation of MRI Versus CT as Diagnostic Imaging Strategies in Patients With Suspected Ischemic Stroke: the MAGRITTE Study.

ConditionStroke
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFondation Ophtalmologique Adolphe de Rothschild

About this trial

Acute ischemic stroke (AIS) is a leading cause of death and long-term disability worldwide. In patients with suspected large vessel occlusion, rapid diagnosis and reperfusion therapy are critical, as treatment delays are associated with worse functional outcomes and increased mortality. Current French guidelines recommend brain magnetic resonance imaging (MRI) as the reference imaging modality because of its high diagnostic accuracy. However, MRI availability remains limited in many stroke centers, often resulting in delays in diagnosis and treatment. Conversely, computed tomography (CT) is more widely available and can substantially shorten time to reperfusion, although it may be less sensitive for early ischemic changes.

The MAGRITTE study aims to determine whether an initial CT-based imaging strategy is more cost-effective than an MRI-based strategy for patients with suspected severe acute ischemic stroke within 6 hours of symptom onset.

This is a prospective, multicenter, randomized controlled trial with two parallel groups enrolling 600 adult patients presenting with a high suspicion of acute ischemic stroke due to proximal large vessel occlusion (National Institutes of Health Stroke Scale \[NIHSS\] score ≥10). Participants will be randomized to undergo either CT with CT angiography or MRI with MR angiography as the first-line diagnostic imaging examination. Additional perfusion imaging may be performed at the investigator's discretion.

The primary objective is to compare the cost-utility of the two diagnostic strategies at 12 months, expressed as the incremental cost per quality-adjusted life year (QALY) gained, using EQ-5D-5L-derived utilities. Secondary objectives include lifetime cost-effectiveness modeling, 5-year budget impact analysis, comparison of functional outcomes, mortality, imaging-to-treatment and reperfusion times, symptomatic intracranial hemorrhage, diagnostic accuracy, management pathways, adverse events, radiation exposure, and healthcare costs.

The study will provide evidence on whether a CT-first imaging strategy can improve the efficiency of acute stroke care while maintaining favorable clinical outcomes and reducing healthcare costs.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years

Symptoms consistent with suspected acute ischemic stroke due to proximal large vessel occlusion

National Institutes of Health Stroke Scale (NIHSS) score ≥10 at admission

Symptom onset <6 hours before randomization

Disqualifiers

Previous diagnostic brain imaging performed within the preceding 24 hours for the index stroke event

Contraindication to MRI (e.g., cardiac pacemaker, metallic implant or foreign body, surgical clips) or CT (e.g., pregnancy, severe renal impairment)

Contraindication to iodinated contrast agent (e.g., known severe allergy)

Not affiliated with the French national health insurance system

Trial design

Design model

Parallel

Treatments tested in this trial

  • CT and CT angiography (CTA)

    Diagnostic test

    Participants randomized to this intervention undergo first-line non-contrast brain computed tomography (CT) and CT angiography (CTA) for the diagnosis of suspected acute ischemic stroke.

  • MRI and MR angiography (MRA)

    Diagnostic test

    Participants undergo first-line brain magnetic resonance imaging (MRI) and MR angiography (MRA) for the evaluation of suspected acute ischemic stroke.

Treatment groups

600 Participants
are divided into 2 treatment groups
Group A: First-line non-contrast CT and CT angiography for suspected acute ischemic stroke.Experimental treatment 1 intervention
Group B: First-line brain MRI and MR angiography for suspected acute ischemic stroke.Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Incremental cost per quality-adjusted life year (QALY) gained at 12 months

Time frame
12 months after stroke onset

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fondation Ophtalmologique Adolphe de Rothschild

Lead sponsor

Université Paris Descartes- Laboratoire Interdisciplinaire de Recherche Appliquée en Économie-Gestion et Santé - LIRAES

Collaborator

This trial is not recruiting at the moment. You can still explore other options: